Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Inclusion Criteria

• •PROCUREMENT Inclusion
• •Any patient, regardless of age\* or sex, with measurable EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype)\^ or EBV (associated)- T/NK- or B cell lymphoproliferative disease
• •\^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an autologous hematopoietic cell transplantation are also eligible for this study.
• •EBV positive tumor (can be pending)
• •Weighs at least 12kg
• •Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given a copy of informed consent.
• •Life expectancy of greater than 6 weeks.
• •TREATMENT Inclusion
• •\- Any patient, regardless of age\* or sex, with measurable EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype)\^ or EBV (associated)-T/NK- or B cell lymphoproliferative disease
• •\^ Patients with relapsed or refractory lymphoma who failed or are ineligible for an autologous hematopoietic cell transplantation are also eligible for this study.
• •And
• •Hodgkin's lymphoma patients in second relapse or first relapse and refractory to at least two lines of salvage chemotherapy including Brentuximab Vedotin or primary refractory disease after at least two lines therapy or
• •Non- Hodgkin's lymphoma patients in first relapse and/or refractory to at least one salvage chemotherapy or with primary refractory disease after at least two lines of therapy or in second or subsequent relapse or
• •T/NK- or B lymphoproliferative disease in first relapse and/or refractory to at least one salvage chemotherapy or with primary refractory disease after at least two lines of therapy or in second or subsequent relapse
• •EBV positive tumor
• •Patients with life expectancy \>/= 6 weeks.
• •Patients with bilirubin less than or equal to 3x upper limit of normal
• •AST less than or equal to 5x upper limit of normal
• •Hgb more than 8.0 (may be a transfused value).
• •Patients with a creatinine less than or equal to 2x upper limit of normal for age
• •Pulse oximetry of more than 90% on room air
• •Patients should have been off other investigational therapy for 4 weeks prior to entry in this study.
• •Patients with a Karnofsky/Lansky score of \>/= 60
• •Recovered from acute toxic effects of prior chemotherapy at least one week before entering the study.
• •Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
• •Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given a copy of informed consent.